Translocations involving the MLL gene on chromosome 11q23 occur in 5-10% of human leukemias, and involve fusion with more than 30 different partner genes. The MLL-AF10 fusion produced by the t(10;11)(p12;q23) or ins(10;11)(p12;q23q13) occurs in a small percentage of acute leukemias, most commonly acute myelogenous leukemia (AML) of the M5 FAB subtype. We report two cases of AML (M5a and M0) and one case of acute lymphoblastic leukemia containing MLL-AF10 fusion. Each case had varied clinical characteristics, despite expressing similar MLL-AF10 fusion transcripts. Including the three cases described in this report, we identified a total of 38 cases of leukemia with MLL-AF10 fusion. Approximately one-third of these are not M5 AML. Taken together, these findings emphasize that while the sentinel molecular event may be identical in a disease, the clinical presentation and outcome can vary widely.
Introduction
In hematologic malignancies, specific chromosomal translocations and their resultant molecular abnormalities are frequently associated with similar clinical features. In some cases the correlation between genotype and phenotype is particularly tight. For example, the t(15;17)(q22;p21) and PML-RAR␣ fusion are present in Ͼ95% of cases of acute promyelocytic leukemia and are not detected in other malignancies. 1 Similarly, the t(1;19)(q23;p13) and E2A-PBX1 fusion is seen almost exclusively in pre-B cell acute lymphoblastic leukemias (ALL) that are arrested at a particular stage of lymphoid differentiation and share a common complex pattern of cell surface antigen expression. 2, 3 Translocations that fuse the 11q23 gene MLL (also known as ALL-1, HRX or HTRX-1) to one of over 30 different partner genes occur in 5-10% of leukemias. [4] [5] [6] MLL translocations occur in both ALL and acute myeloid leukemia (AML), but certain translocations tend to be preferentially associated with common clinical features. 6 The t(4;11)(q21;q23) occurs almost exclusively in ALLs which are typically CD10-negative and express one or more myeloidassociated cell surface antigens. 7, 8 In contrast, the t(9;11)(p22;q23) is observed primarily in AMLs with monocytic features (FAB M4 and M5 subtypes). 9, 10 Translocations between the long arm of chromosome 11 (q14-q23) and the short arm of chromosome 10 (p11-p13) occur in both ALL and AML and result in several different gene fusion events. Chaplin and colleagues 11 originally cloned MLL-AF10 fusion cDNAs from a patient with AML and a t(10;11)(p12;q23). Subsequently, this group showed that MLL-AF10 fusion was present in eight of eight patients with M4 or M5 AML and simple or complex versions of the t(10;11). 12 In this latter study, six of eight patients had either a three-way 13 demonstrated that MLL and AF10 are in opposite transcriptional orientations on chromosomes 11 and 10, respectively, thereby necessitating complex rearrangement with inversion of either 10p or 11q to create an in-frame fusion protein. A second rearrangement is the t(10;11)(p11.2;q23) which has been shown to fuse MLL to ABI1 in one patient with M4 AML.
14 The t(10;11)(p13;q14) was shown to fuse AF10 to CALM in U937, a cell line derived from a diffuse histiocytic lymphoma. 15 Subsequently, CALM-AF10 fusion has been identified in both AML and ALL. [16] [17] [18] [19] Because of this genetic heterogeneity, detailed molecular or FISH studies are required to define the molecular event present in patients with a t(10;11). Since most cases of MLL-AF10 fusion reported to date have occurred in patients with AML-M5, it has been suggested that MLL-AF10 and CALM-AF10 fusion are associated with distinct subsets of acute leukemia. 17, 20, 21 In this report, we describe three children who were diagnosed with leukemia, M0 and M5a AML and B-precursor ALL. While all three cases were characterized by MLL-AF10 fusion, they were associated with a variety of clinical manifestations. We then reviewed the published literature, revealing a total of 38 cases of leukemia, including the three described herein, with documented MLL-AF10 fusion and/or a complex (10;11) translocation involving an inversion of chromosome 11q23. Overall, 68% of these cases were M5 AML, but the remainder included mixed lineage leukemia, ALL, and AML of M0, M1, M2, M4 and M7 subtypes, emphasizing the dysequilibrium between genotype and phenotype that may occur in leukemias with this molecular abnormality.
Materials and methods

Specimens
Patients 1 and 2 had bone marrow cytogenetic analyses and reverse transcriptase-polymerase chain reaction (RT-PCR) screening for chromosomal translocations performed at initial presentation. Patient 3 had molecular analyses performed following relapse, after a t(10;11) was detected by standard cytogenetics at diagnosis. All analyses were approved by the Colorado Multiple Institution Review Board.
Cytogenetics and fluoresence in situ hybridization (FISH)
Giemsa-banded cytogenetic studies were performed from unstimulated cultures of bone marrow. Samples were prepared using a direct technique and overnight culture methods as described previously. 22 
Molecular analyses
For case 1, MLL-AF10 fusion was initially detected using a multiplex PCR chromosomal translocation screening kit (DNA Technologies, Aarhus, Denmark) based on previously described methods. 25 These results were confirmed, and other cases were analyzed with nested RT-PCR assays as previously described. 16 Primer sequences are listed in Table 1 . Nucleotide and exon numbers are per Chaplin et al 11 for AF10 and Nilson et al 26 for MLL. To confirm the integrity of isolated RNA, a portion of Abl cDNA was amplified using previously described primers. 27 Reactions lacking input cDNA were also amplified as negative controls.
To determine the nucleotide sequence of PCR products, 1 l was ligated into the pCR2.1 or pCR2.1-TOPO vector (Invitrogen, Carlsbad, CA, USA) and used to transform competent bacteria exactly as suggested by the manufacturer. Antibiotic-resistant bacteria containing vectors with inserts of the appropriate size were identified and nucleotide sequences were determined on both strands using an ABI 377 automated sequencer. Data base searches were performed using the BLAST algorithm from the National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov/BLAST/). 
Case 1
A 22-month-old female had a 6-month history of intermittent fever, weight loss, malaise and irritability. Her initial hemoglobin was 6.9 g/dl, hematocrit 20.6%, and platelet count 138 000/l. Her white blood count was 5.5 × 10 9 /l with 93% lymphocytes, 2% monocytes, 2% reactive lymphocytes, and 3% very large, vacuolated monocytoid cells. She had laboratory evidence of disseminated intravascular coagulation (DIC). Bone marrow aspirate and biopsy showed a hypercellular marrow with 77% blasts. Acid phosphatase and non-specific esterase were positive. Myeloperoxidase was negative. The leukemic cells expressed CD33, and were negative for CD1, CD2, CD7, CD9, CD10, CD13, CD14, CD20, CD34, HLA-DR and TdT. A diagnosis of acute monoblastic leukemia (AML, FAB subtype M5a) was made. Cytogenetic studies showed a karyotype of 87,XXX,−X,i(1)(q10), −3,−7,−9,−15 [8]/90,XXXX,i(1)(q10),add(2)(p11.2),−15,−16 [4] /46,XX [5] . The patient's parents did not consent to intensive chemotherapy. The child was treated palliatively at home and died 2 weeks later.
Case 2
A 16-month-old Hispanic female with prolonged bleeding from a minor abrasion had an initial hematocrit of 19%, platelet count of 8000/l and a white blood count of 162 × 10 9 /l with 93% blasts of lymphoid morphology. Bone marrow aspirate and biopsy showed a hypercellular marrow replaced with myeloperoxidase negative leukemic cells that were HLA-DR and CD19 positive, were dimly positive for CD10, and did not express CD2, CD7, CD13, CD20, CD33, CD34, or TdT. A diagnosis of B-precursor ALL was made. Cytogenetic studies showed 46,XX,ins(10;11)(p12;q23q13) [5] /46,XX [13] . The patient received induction chemotherapy with prednisone, Lasparaginase, vincristine, and daunomycin. She was classified as a slow early responder with 56% blasts on bone marrow aspirate performed at day 7.
28 She achieved complete remission by day 28. She underwent a matched-sibling cord blood transplant 1 year following diagnosis, and is currently in clinical and cytogenetic remission 8 months post-transplant.
Case 3
A 4-month-old girl with a 2-day history of irritability had a matted, draining right eye and hepatomegaly. Her hemoglobin was 11.3 g/dl, hematocrit 33%, platelet count 75 000/l and white blood count 59.9 × 10 9 /l with 80% blasts. Bone marrow aspirate showed Ͼ90% blasts without Auer rods, that were myeloperoxidase and ␣-naphthyl butyrate negative. The blasts were HLA-DR, CD7, CD10, CD15, CD33 and CD34 positive and CD2, CD13, CD19, CD20, and TdT negative. Cytoplasmic CD3 and CD61 were negative. The leukemia was classified as AML, FAB subtype M0. There was no evidence of CNS leukemia. Cytogenetic studies showed a karyotype of 46,XX,ins(10;11)(p12;q23q13) [24] /46,XX [1] , with three MLL signals in 41% of cells on interphase FISH.
After two cycles of intensive timing chemotherapy, 29 she had a bone marrow and ocular recurrence. She received aggressive re-induction therapy including anterior chamber radiation therapy, and subsequent marrow evaluation showed a second complete remission. During this time, a suitably matched, unrelated cord blood unit was identified, and her care was transferred to The Children's Hospital. During pretransplant evaluation performed 2 weeks after her previous studies, the patient was found to have biopsy-proven leukemia cutis. Bone marrow aspirate at the same time showed patchy leukemic involvement. Standard cytogenetic analysis revealed the ins(10;11) seen previously with a new t(1;13)(q25;q14) in 11 of 20 metaphases. Over the next several days, she developed two additional skin lesions, and a rock-hard right inguinal lymph node, which rapidly grew to 3 cm × 4 cm. CT scans showed no intracranial chloroma, but significant inguinal, retroperitoneal and pelvic lymphadenopathy.
The patient was treated with myeloablative chemoradiotherapy, including total body irradiation (1200 cGy in six fractions) with a 1000 cGy boost to the skin lesions, cyclophosphamide (30 mg/kg × two doses), and cytosine arabinoside (2.5 g/m 2 × six doses), followed by infusion of unrelated cord blood stem cells. She had an uncomplicated transplant course and was discharged from hospital on day +23. A bone marrow aspirate at day +28 showed no evidence of leukemic cells, and molecular chimerism studies showed Ͼ98% donor cells. Three MLL signals were seen in 1.7% of cells by interphase FISH (similar to background levels), but standard cytogenetic studies later identified 1/20 cells to have the ins(10;11) and several new numerical abnormalities. The next day, the patient developed new inguinal adenopathy and a 4-mm red nodule on the scalp. One day later, she developed DIC and thrombocytopenia. Bone marrow studies on day +35 had 69% leukemic blasts, and three MLL signals in 13.2% of nuclei. Molecular studies documented progressive loss of donor cell reconstitution. The patient received palliative care and died of progressive disease 1 week later.
Results and discussion
An ins(10;11)(p12;q23q13) was identified as the sole cytogenetic abnormality present at diagnosis in patients 2 and 3 ( Table 2) . Interphase FISH performed on bone marrow samples from these patients showed three MLL signals, consistent with an MLL translocation. In contrast, patient 1 had a near tetraploid karyotype with structural abnormalities and without visible abnormalities of chromosome 10 or 11. MLL-AF10 fusion was identified in patient 1 when the diagnostic marrow specimen was analyzed with a commercial multiplex PCR chromosome translocation screening kit. FISH studies (Table 2) . Patients 1 and 3 had so-called type I MLL-AF10 fusion transcripts, with fusion between MLL exon 8 or 9 and 5′ regions of AF10 (position 979 or 883). Products were obtained with both type I and type II MLL-AF10 PCR primers from patient 2. Cloning and sequencing of the PCR products showed that both were derived from bona fide MLL-AF10 fusion transcipts. The type II fusion transcripts contained MLL exon 9 fused to AF10 nucleotide 2110. The type I transcripts fused MLL exon 8 and portions of exon 9 to AF10 nucleotide 899 or 979. We presume that these arose by differential splicing and not as two independent gene fusion events. Presence of both types of transcripts would necessitate that the genomic breakpoint occurs within the region of AF10 affected by type I breakpoints; a type II breakpoint would remove all 5′ regions of AF10.
In previous studies, MLL-AF10 fusion has been described almost exclusively in patients with AML, predominantly of the M5 subtype. Only one case of ALL has been reported associated with documented MLL-AF10 fusion. 30 In contrast, each of the three patients we describe had distinct clinical characteristics, despite containing similar MLL-AF10 fusion transcripts. One patient had classic monoblastic leukemia (FAB M5a) with a near tetraploid karyotype not previously described in association with MLL-AF10 fusion, one had AML with minimal differentiation (M0), and one had B-precursor ALL.
This variety of clinical characteristics prompted us to review the literature for other leukemias with MLL-AF10 fusion and for which the subtype of leukemia was characterized. To avoid confusion, we included only cases with documented MLL-AF10 fusion and those containing complex (10;11) translocations, with inversion of chromosome 11q23, but for which no molecular studies were reported. These latter rearrangements appear to be specific for MLL-AF10 fusion. 13 Including the three cases we describe, we found 38 leukemias fitting these criteria: 19 with documented MLL-AF10 fusion and 19 that met the above cytogenetic criteria (Table 3) . Twenty-six of these 38 leukemias (68%) were FAB M5 or M5a AML, two were M4 AML (5%), two (5%) were immature (M0 or M1) AML, and three (8%) were ALL. There was one case each of M2 AML, M7 AML, AML with subtype not specified, biphenotypic leukemia, and leukemia not specified. Thus while we agree that there is a strong association with M5 AML, this linkage is not absolute and the presence of differing phenotypes should not be considered as evidence against MLL-AF10 fusion. Our patient 2 is the third described with type II MLL-AF10 fusion. While our patient had ALL, the other two patients had M5 AML, suggesting no obvious linkage between the breakpoint location in AF10 and disease phenotype.
Clinical heterogeneity has also been appreciated in patients with leukemia and CALM-AF10 fusion. Initial reports suggested this molecular abnormality was observed primarily in patients with T cell ALL or immature (M0 or M1) AML. Recently, CALM-AF10 fusion has been reported in patients with T cell lymphoblastic lymphoma, AML-M4, AML-M5 and biphenotypic leukemia, in addition to those with T-ALL, AML-M0 and AML-M1. [16] [17] [18] 31, 32 One case of MLL-ABI1 fusion has been reported to date in a patient with AML-M4.
14 There is also a reported case of M5 AML, where splitting of AF10 resulted in both MLL-AF10 and AF10-HEAB fusions due to the insertion of 11q12 to 11q23. 33 These data clearly indicate there is no definitive association between genotype and phenotype in patients with (10;11) translocations and that RTLeukemia PCR and/or detailed FISH studies are necessary to delineate the specific fusion events present in each case.
There are suggestions in the literature that a (10;11) translocation, with any molecular abnormality, is associated with a very poor treatment outcome. 17, 18 While the clinical course of patient 3 was indicative of an aggressive, treatment-resistant leukemia, we believe that the data published to date are inconclusive regarding this issue. Additional studies of this question are warranted and should include detailed characterization of the molecular events present in each case. Accurate conclusions regarding treatment outcome can only be made through analysis of patients with similar molecular abnormalities treated prospectively in a uniform manner.
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